Delocamten vs Mavacamten

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Cardiac myosin (inhibitor) · full Heart Failure pipeline

Delocamten

Developed by Bristol-Myers Squibb

Phase 2 in Heart Failuresmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06122779 (registry estimate)

No aligned efficacy figure on record for this race.

Mavacamten · Camzyos

Marketed by Bristol-Myers Squibb

Phase 2 in Heart Failuresmall molecule
Weak signal

NCT04766892 · Phase 2 · completed

The study enrolled 30 participants in a single mavacamten arm with no randomization, blinding, or placebo/active comparator. Its primary outcomes were descriptive safety measures and biomarker changes rather than a hard clinical endpoint, so the reported findings cannot provide a controlled estimate of mavacamten’s benefit.

Reported efficacy

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (From the first dose of study drug through 56 days following last dose of study drug (assessed for an average of 225 days up to a max of approximately 270 days)); Number of Participants With Adverse Events of Special Interest (AESIs) (From the first dose of study drug through 56 days following last dose of study drug (assessed for an average of 225 days up to a max of approximately 270 days)); Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) (From the first dose of study drug through 56 days following last dose of study drug (assessed for an average of 225 days up to a max of approximately 270 days)); Number of Participants With Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) (From the first dose of study drug through 56 days following last dose of study drug (assessed for an average of 225 days up to a max of approximately 270 days)); Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) (From the first dose of study drug through 56 days following last dose of study drug (assessed for an average of 225 days up to a max of approximately 270 days)); Number of Participants With Cardiac Rhythm Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) (From the first dose of study drug through 56 days following last dose of study drug (assessed for an average of 225 days up to a max of approximately 270 days)); Ratio to Baseline at Week 26 in Resting N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) Levels; Ratio to Baseline at Week 26 in Resting High Sensitivity Cardiac Troponin T (Hs-cTnT) Levels Assessed by High-Sensitivity Assay: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (From the first dose of study drug through 56 days following last dose of study drug (assessed for an average of 225 days up to a max of approximately 270 days)): Mavacamten 23 Participants (not_applicable)

Result source: NCT04766892

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDelocamtenMavacamten
CV death or HF hospitalisation—Not reported—Not reported
HF hospitalisation—Not reported—Not reported
CV death—Not reported—Not reported
KCCQ clinical summary, change—Not reported—Not reported

CV death or HF hospitalisation

Delocamten
—Not reported
Mavacamten
—Not reported

HF hospitalisation

Delocamten
—Not reported
Mavacamten
—Not reported

CV death

Delocamten
—Not reported
Mavacamten
—Not reported

KCCQ clinical summary, change

Delocamten
—Not reported
Mavacamten
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Delocamten: no structured comparison results are available for Heart Failure.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Delocamten: 0 of 4 rows · Mavacamten: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricMavacamten
Dropout rate
20%
NCT04766892 · Phase 2 · monotherapy · Heart Failure, Heart Failure with Preserved Ejection Fraction · phase 2
Discontinued due to AEs
10%
NCT04766892 · Phase 2 · monotherapy · Heart Failure, Heart Failure with Preserved Ejection Fraction · phase 2
Serious AEs
16.7%
NCT04766892 · Phase 2 · monotherapy · Heart Failure, Heart Failure with Preserved Ejection Fraction · phase 2
Most frequent reported AEs
covid-19 13.3%
dizziness 13.3%
fall 13.3%
NCT04766892 · Phase 2 · monotherapy · Heart Failure, Heart Failure with Preserved Ejection Fraction · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Delocamten's landscape · Mavacamten's landscape